Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Company Overview

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

Key Stats

• Today's Range: $28.75 to $30.97
• 50-Day Range: $22.33 to $30.86
• 52-Week Range: $19.05 to $32.56
• Volume: 2.82 million shs
• Average Volume: 1.96 million shs
• Market Capitalization: $3.78 billion
• P/E Ratio: 18.26
• Dividend Yield: N/A
• Price Target: $34.00
• Consensus Rating: Strong Buy

Catalyst Pharmaceuticals Stock Analysis - MarketRank™

Catalyst Pharmaceuticals scored higher than 95% of companies evaluated by MarketBeat, and ranked 20th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Catalyst Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 3 strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Catalyst Pharmaceuticals has a consensus price target of $34.00, representing about 10.2% upside from its current price of $30.86.

Amount of Analyst Coverage

Catalyst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 16.67%

Earnings Growth

Earnings for Catalyst Pharmaceuticals are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Catalyst Pharmaceuticals is 18.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of Catalyst Pharmaceuticals is 18.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.91.

Price to Earnings Growth Ratio

Catalyst Pharmaceuticals has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Catalyst Pharmaceuticals has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.76% of the float of Catalyst Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.92.

Change versus previous month

Short interest in Catalyst Pharmaceuticals has recently decreased by 7.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Catalyst Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Catalyst Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.76

News Sentiment

Catalyst Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Catalyst Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

17 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.

MarketBeat Follows

10 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CPRX Stock Analysis - Frequently Asked Questions

How have CPRX shares performed this year?

Catalyst Pharmaceuticals' stock was trading at $23.34 on January 1st, 2026. Since then, CPRX stock has increased by 32.2% and is now trading at $30.86.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its earnings results on Thursday, November, 6th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.18. The biopharmaceutical company earned $148.39 million during the quarter, compared to analyst estimates of $136.79 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 36.47% and a net margin of 36.39%.
Read the conference call transcript.

Is Catalyst Pharmaceuticals doing a stock buyback?

Catalyst Pharmaceuticals' Board of Directors authorized a share buyback plan on Wednesday, October 1st 2025, which authorizes the company to buy back $200,000,000 in shares, according to EventVestor. This means that the company could purchase up to 8.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Who are Catalyst Pharmaceuticals' major shareholders?

Top institutional shareholders of Catalyst Pharmaceuticals include Bank of New York Mellon Corp (0.56%), Principal Financial Group Inc. (0.55%), Advisors Preferred LLC (0.31%) and Moran Wealth Management LLC (0.14%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Brian Elsbernd, Richard J Daly, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper.
View institutional ownership trends.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/06/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CPRX
• CIK: 1369568
• Web: www.catalystpharma.com
• Phone: (305) 420-3200
• Fax: 305-529-0933
• Employees: 80
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Catalyst Pharmaceuticals: $34.00
• High Price Target: $35.00
• Low Price Target: $33.00
• Potential Upside/Downside: +10.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.69
• Trailing P/E Ratio: 18.26
• Forward P/E Ratio: 11.69
• P/E Growth: 0.94
• Net Income: $214.33 million
• Net Margins: 36.39%
• Pretax Margin: 48.14%
• Return on Equity: 36.47%
• Return on Assets: 31.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.08
• Quick Ratio: 5.82

Sales & Book Value

• Annual Sales: $588.99 million
• Price / Sales: 6.41
• Cash Flow: $3.12 per share
• Price / Cash Flow: 9.90
• Book Value: $7.76 per share
• Price / Book: 3.98

Miscellaneous

• Outstanding Shares: 122,350,000
• Free Float: 109,423,000
• Market Cap: $3.78 billion
• Optionable: Optionable
• Beta: 0.72